Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Sana Biotechnology (NASDAQ: SANA) will present at the 44th Annual J.P. Morgan Healthcare Conference with a live webcast on Wednesday, January 14, 2026 at 9:45 a.m. PT.
The presentation will include a business overview and update delivered by Steve Harr, president and chief executive officer. The webcast and a replay will be available on Sana's Investor Relations website, with the replay accessible for 30 days after the conference.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SANA declined 4.44%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.5% during that session. Our momentum scanner triggered 38 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $60M from the company's valuation, bringing the market cap to $1.29B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SANA gained 7.39% while several gene/cell therapy peers were mixed: IOVA +6.13%, TSHA +7.57%, QURE +3.92%, NKTR +1.33%, and URGN -0.50%. Momentum scanner only flagged TNGX at -7.21% with no news, supporting a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Preclinical data publication | Positive | -9.8% | Nature Biotechnology preclinical fusogen HSC gene-editing data and platform expansion. |
| Nov 24 | Conference participation | Neutral | -0.8% | Announcement of December 2025 investor conference webcasts and business updates. |
| Nov 06 | Earnings and pipeline | Positive | +1.0% | Q3 2025 results with lower expenses, cash runway into late 2026, and pipeline focus. |
| Nov 04 | Conference participation | Neutral | -1.7% | TD Cowen summit presentation announcement with webcast and 30-day replay. |
| Aug 26 | Conference participation | Neutral | +4.7% | September 2025 series of investor conference presentations and webcasts. |
Conference appearance announcements have historically had modest to negative single-day reactions, while more substantive R&D or financing events have shown mixed responses.
Over the last six months, Sana reported multiple milestones and financing steps. Q3 2025 results on Nov 6 highlighted lower operating expenses, a narrower loss, and prioritization of SC451 and SG293, with a 0.99% price gain. An August 2025 capital raise via underwritten offering increased liquidity. Scientific visibility improved with a Dec 8 publication in Nature Biotechnology, though shares fell 9.75% after that news. Several investor conference presentations from August–December 2025 saw small, mixed price moves.
Market Pulse Summary
This announcement highlighted Sana’s upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, with a webcast at 9:45 a.m. PT and a 30-day replay. In recent months, the company reported pipeline prioritization, significant financing transactions, and a high-profile publication in Nature Biotechnology. Investors following this news may focus on how the JPM overview updates those prior financial and R&D disclosures and whether management reiterates or refines timelines and resource allocation.
AI-generated analysis. Not financial advice.
SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.
The webcast will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replay of the presentation will be available at the same location for 30 days following the conference.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the Company’s participation at the 44th Annual J.P. Morgan Healthcare Conference; and the subject matter of the Company’s presentation at the conference. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated November 6, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
When will Sana Biotechnology (SANA) present at the J.P. Morgan Healthcare Conference?
Who will deliver Sana Biotechnology's (SANA) presentation at the January 14, 2026 webcast?
Where can investors watch the Sana (SANA) webcast for the J.P. Morgan Healthcare Conference?
Will there be a replay of Sana Biotechnology's (SANA) J.P. Morgan presentation and for how long?
What topics will Sana (SANA) cover in the January 14, 2026 presentation?
Is the Sana (SANA) presentation at J.P. Morgan open to the public via webcast?
